Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III—rationale, trial design and baseline data
2016; Oxford University Press; Linguagem: Inglês
10.1093/ndt/gfw321
ISSN1460-2385
Tópico(s)Dialysis and Renal Disease Management
ResumoBackgroundPatients with chronic kidney disease (CKD) are at risk of progression to end-stage renal disease and cardiovascular disease. Data from other populations and animal experiments suggest that neprilysin inhibition (which augments the natriuretic peptide system) may reduce these risks, but clinical trials among patients with CKD are required to test this hypothesis.
Referência(s)